Pulmonology experts update their knowledge on the latest treatments in COPD as well as the management of the ecobronscopia.

-These days have enabled specialists improve their handling in the realization of ecobroncoscopia, new tool for diagnosing cancer bronchopulmonary, very safe and with a high diagnostic yield

Seville, January 2013.- the disease chronic obstructive pulmonary (COPD) affects nearly two million people in Spainbeing the main consequence of smoking in our country and its surroundings. Dyspnoea and exercise intolerance are some of its most crippling symptoms, which are closely related to bronchial obstruction and air entrapment, which then translates, medium to long term, even with a high degree of mortality and a decrease in cardiac pumping ability. Bronchodilators are the most effective drugs to treat this pathology as they manage to control successfully the clinical symptoms, improve lung function, reduce exacerbations and improve the quality of life of patients affected by COPD.

Dr. Francisco Casas, President of NEUMOSUR and director of the first regional Conference of COPD, during the inauguration of them.

So this past weekend during the holding of the first Conference of COPD held in Seville, and organised by the Association of Pneumology and surgery thoracic South (NEUMOSUR), whose specialists presented the latest in the respect in the treatment of this respiratory pathology exposed. In this sense, be advanced that the development of new bronchodilators of long duration (LABA, adrenergic, and LAMA, anticolergenicos, according to its acronym in English) allow a significant improvement in the treatment of this disease, which contributes to a better outcome for the patient and a decrease in health care costs. In certain patients, that improvement may be greater if combine these drugs among themselves or with inhaled corticosteroids.

The COPD Conference held in Seville, coordinated by Dr. Francisco Casas, President of NEUMOSUR, have also served the specialists in the treatment of respiratory diseases to improve their skills in the accomplishment of ecobroncoscopias, new tool for the diagnosis of bronchopulmonary, very safe cancer and with a high diagnostic yield. However, the specialists gathered in Seville indicate that this profitability can be enhanced through the implementation of protocols that allow process and study samples obtained quickly.